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Abstract 
Background and aims: PSC is currently thought to be an immune-mediated disease, 
where both host genes and environmental factors interact.  Some, but not all, of the host 
immunoregulatory genes responsible for individual susceptibility to PSC, have been 
identified. The co-stimulatory receptor gene cluster on chromosome 2q33 encodes both 
the positive T cell regulators; CD28 and ICOS, and the negative regulator; CTLA4. The 
CTLA4 gene has been implicated in several immune mediated diseases, but it is not 
known whether PSC is associated with any of these genes. Methods: We performed 
PCR-based genotyping on 144 PSC patients and 285 controls. We investigated two 
single nucleotide polymorphisms in the CTLA4 gene and six microsatellites covering 
approximately 262 kb of the flanking regions, including the ICOS and CD28 genes. 
Results: Overall there were no statistically significant differences between PSC 
patients and controls comparing genotype and allele frequencies for the CTLA4 +49AG 
and CT60 SNPs or for the CD28-A, CD28-B, SARA43, SARA1, SARA31, SARA47 
microsatellite markers. Nor were any associations with clinical subgroups observed. 
Conclusion: There are no major effects of the CD28/CTLA4/ICOS gene region on 
susceptibility to primary sclerosing cholangitis. However, minor contributions 
(OR<1.8) cannot be excluded. 
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Introduction 
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized 
by fibrosis and strictures of the intra- and/or extra-hepatic bile ducts (1). The etiology is 
unknown. Patients have increased risk of developing malignancies, especially 
cholangiocarcinoma which is seen in 10 to 14% of the patients (2) . PSC is also 
strongly associated with inflammatory bowel disease (IBD), mainly ulcerative colitis 
(UC), which may affect up to 80% of the patients in Northern Europe (3). Increased 
prevalence of other autoimmune diseases, (4) combined with observations of abnormal 
immune regulation (5) and the genetic association with specific HLA haplotypes (6) all 
suggest that PSC is an immune mediated disease.  
 
PSC is considered a “complex disease” whereby inheritance of one or more specific 
genetic polymorphisms is associated with an increased risk of disease (7). Current 
candidate genes include various immunoregulatory genes; both HLA- and non-HLA 
genes. Genes most probably also contribute to the observed clinical phenotypic 
heterogeneity in PSC and confounds our understanding of the disease. 
 
Chromosome 2q33 encodes three important immunoregulatory genes; the cytotoxic T 
lymphocyte-antigen 4 gene (CTLA4), the cluster of differentiation 28 gene (CD28) and 
the inducible co-stimulatory gene (ICOS) (8) (Figure 1). These genes encode three T 
cell molecules which are all important for activation and regulation of T cells and 
adaptive immunity. The CD28 molecule is required for optimal proliferation and 
maturation of the T cell upon activation. Activation of the ICOS molecule modulates T-
cell activity while CTLA-4 competes with CD28 for binding to the antigen presenting 
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cell (APC) and activation through CTLA-4 down-regulates the T-cell response (9). The 
balance between these various receptor-ligand interactions determines the magnitude of 
the immune response.   
 
The 2q33 region has been linked with various immune mediated diseases through both 
linkage and association studies (10). Thus, CTLA4, CD28 and ICOS are all potential 
candidate genes for such diseases. CTLA4 polymorphisms have been associated with a 
number of autoimmune diseases, including type I diabetes, Grave’s disease (10) and the 
liver diseases primary biliary cirrhosis (PBC) (11) and autoimmune hepatitis (AIH)(12). 
The question of whether CTLA4 is involved in susceptibility to PSC has been discussed 
for several years (5-7). Two opposing reports on PSC and the CTLA4 +49AG single 
nucleotide polymorphism (SNP) have been published as abstracts leaving the question 
of whether CTLA4 influences susceptibility to PSC unresolved (13;14).  
 
In a recent study on type I diabetes, Grave’s disease and autoimmune thyroiditis Ueda 
et al. (15) mapped disease susceptibility to 6.1 kb of the 3’region of the CTLA4 gene, 
not including the CTLA4 +49AG SNP. The most strongly associated SNP, the so-called 
CTLA4 CT60 SNP, had only weak effect on either disease. However, the haplotype 
carrying this SNP was found to correlate with lower levels of soluble CTLA-4 
messenger RNA. It is possible that a reduction in CTLA-4 activity may give rise to 
increased T cell mediated self-reactivity. 
 
On this background CTLA4, and also potentially CD28 and ICOS are all interesting 
candidate genes for study in PSC. In the present study we have therefore investigated 
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the 2q33 region with selected genetic markers to evaluate the contribution of these 
genes to disease risk and clinical phenotype in PSC. 
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Materials and Methods 
Patients and controls 
A total of 144 Norwegian PSC patients and 285 healthy Norwegian blood donor 
controls were included in the study. Patients were diagnosed using accepted criteria, all 
having typical findings at endoscopic retrograde cholangiography (ERC) (1). The 
median age at diagnosis was 31.2 years (range 12.3-73.1 years), 75% of the patients 
were male and 79% had concomitant IBD (ulcerative colitis: 74%, Crohn’s disease: 
14%, indeterminate colitis: 12%). Cholangiocarcinoma was seen in 11% of the patients. 
IBD was diagnosed and classified on the basis of endoscopic and histologic criteria (3) 
and the diagnosis of cholangiocarcinoma was based on histology. The study was 
authorized by the Regional Committee for Research Ethics and informed consent was 
obtained from all patients. 
 
Genetic typing 
To analyze the genetic association between PSC and the CTLA4 gene with the flanking 
regions including ICOS and CD28, we performed PCR-based genotyping for six 
microsatellites and two SNPs covering approximately 262 kb of the chromosome 
(Figure 1).  
We selected two common CTLA4 SNPs: the +49 A to G SNP and the more recently 
identified CT60 A to G SNP (15). All genotyping was performed using genomic DNA 
isolated from peripheral blood leukocytes. The CTLA4 +49AG SNP was genotyped 
using TaqMan technology from Applied Biosystems on an ABI Prism 7000 Analyzer 
(Applied Biosystems, Foster City, California, USA).  The CT60 SNP was genotyped 
using a PCR-restriction fragment length polymorphis
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microsatellite markers known as SARA47 (located within intron 4 of the ICOS gene), 
SARA31, SARA1 and SARA43 (also called D2S307) were amplified with primers 
flanking the repeat regions (8). We genotyped two microsatellites in the CD28 region: a 
GT repeat localized centromeric to the CD28 gene referred to as CD28-A (-
9543(GT)11-17) (primer sequence: forward: 5' ggt-atg-tgt-gta-tgc-att-gct-g 3', reverse: 
5' tgg-aat-caa-cac-aag-agt-cca 3'), and a GA repeat localized in intron 1 of the CD28 
gene referred to as CD28-B (+7177(GA)25-30) (primer sequence: forward: 5' ttt-gca-
aat-ggc-tga-gtg-ac 3', reverse: 5' ttt-tcc-tct-ccc-tcc-tcc-tc 3'). Positive and negative 
controls were included in all runs and a minimum of 10% of the samples were tested on 
two separate occasions to determine the reproducibility of the assays. Upon re-testing 
the results were reproducible in 100% of samples. The microsatellite alleles were 
identified by size on an ABI 377 XL DNA sequencer (Applied Biosystems, Foster city, 
California, USA) and named accordingly. Details of methods are available on request. 
 
Statistical analyses 
Earlier studies on PBC (11) and type 1 AIH (12) demonstrated associations for the 
CTLA4 +49AG SNP with odds ratios (OR) of 1.9 and 2.1, respectively. However, Ueda 
et al. found that the CTLA4 CT60 SNP was associated with much smaller effects on 
type 1 diabetes and Grave’s disease (OR=1.14 and 1.51, respectively) (15). To identify 
such weak genetic associations with confidence requires very large numbers of patients. 
PSC is much less common than type 1 diabetes and Grave’s disease and multi-centre 
collections are not available for analysis. Power calculations based on the number of 
samples included showed that the present study had sufficient power (i.e. >80%, 
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significance level 0.05, allele frequencies among controls 0.2 - 0.7) to detect genetic 
associations with OR>1.8. 
 
Due to technical problems 3 patients and 22 controls were not typed for all markers. 
These were excluded from our statistical analyses. Thus, the calculations were done on 
141 patients and 263 controls. Hardy-Weinberg equilibrium was tested using the 
program Arlequin version 2.000 (16). We analysed each locus globally with a χ2 test 
using SPSS 11.0 (SPSS Inc., Chicago, IL, USA). The allele frequencies were then 
analysed at each locus by a χ2 test or Fisher's exact test where appropriate, using the 
same program. To estimate haplotype frequencies we used the expectation-
maximization (E-M) algorithm implemented in the program Cocaphase available at the 
UK HGMP Resource Centre (Cambridge, UK) (http://www.hgmp.mrc.ac.uk). The 
effect was measured by calculating ORs for allele, genotype and haplotype frequencies 
according to Woolf with Haldane's continuity correction. The level of significance was 
set to p=0.05 and all p values were corrected for the number of comparisons (pc) 
(Bonferroni correction).  When the material was divided into subgroups the p values 
were also corrected for the number of subgroups on the occasion. Linkage 
disequilibrium between loci was calculated as normalized global disequilibrium 
statistics (Wn) (17). The values of Wn range from 0 to 1, with values near 1 representing 
strong disequilibrium.  
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Results 
All tested loci were confirmed to be in Hardy-Weinberg equilibrium in both patients 
and controls (data not shown) except the SARA43 locus in patients. The gene and allele 
frequencies in the controls were comparable with those of other published control 
populations (11;12;18).  
 
No significant linkage disequilibrium (LD) was found between the markers (Wn<0.4). 
The LD over the total analysed gene region (between the CD28-A - and SARA47 
markers) was also low (Wn<0.2). LD between the CTLA4 +49AG and CT60 SNP in 
CTLA4 was moderate (Wn=0.5).  
 
We first tested the difference in distribution of alleles between patients and controls at 
each locus by global χ2 analyses. In accordance with the result of the Hardy-Weinberg 
analysis, SARA43 was the only locus where the distribution of alleles deviated 
significantly between patients and controls (Table I). Comparing allele frequencies at 
each locus we saw an increase in the SARA43*220 allele in patients (11%) compared to 
controls (5%), but the difference failed to reach statistical significance when corrected 
for the number of comparisons (OR=2.3, p=0.003, pc=0.08) (Table I). None of the other 
alleles within any of the loci tested were associated to PSC. Since the CTLA4 gene is of 
special interest due to the many previous studies of this gene in autoimmune disease we 
also compared genotype, carrier and haplotype frequencies for the two SNPs tested in 
the CTLA4 gene. No differences were observed comparing patients and controls (Table 
II). Since LD was low between the markers we did no further haplotype analyses.  
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We subsequently divided the patients into subgroups to look for associations with 
clinical phenotypes. There were no associations in PSC patients either with and without 
cholangiocarcinoma, or with and without ulcerative colitis for any of the alleles tested 
(data not presented). To look for epistatic interactions we also stratified our material for 
the HLA-DRB1*0301-MICA*5.1-MICB*24 haplotype which we previously have found 
to be associated to PSC (19). (Data were available for all patients and 256 of the 
controls.) This could be of special interest since CD28, CTLA4 and ICOS molecules act 
in concert with the HLA molecule in the initiation and regulation of the immune 
response. However, there were no significant differences in distribution of alleles at the 
different loci between PSC patients with and without the HLA-DRB1*0301-MICA*5.1-
MICB*24 haplotype. 
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Discussion 
In this study we have analysed selected genetic polymorphisms within the CTLA4, 
CD28 and ICOS genes in a large single centre series of PSC patients to assess whether 
these genes play a role in determining either disease susceptibility or disease 
phenotype. We found no firm evidence of association of PSC with any of the 
polymorphisms tested. 
 
The global χ2 analyses indicated an association of PSC to the SARA43 locus. 
Comparing allele frequencies at this locus, the SARA43*220 allele appeared to be 
increased in patients compared to controls (11% vs. 5%), however, the difference was 
not statistically significant when corrected for the number of comparisons (pc=0.08). 
Studies of other immune-mediated diseases and SARA43 polymorphisms have also 
failed to identify association to this genetic marker (20). 
 
The CTLA4 +49AG SNP is the most studied genetic marker in this region of 
chromosome 2q33. The CTLA4 +49G allele of this SNP has been found to be 
associated with several autoimmune diseases (10) including PBC (11) and type I AIH 
(12). However, this association is not universal in autoimmune diseases (10) and 
preliminary reports in PSC have been contradictory (13;14). In the present study there 
were no statistically significant differences in the frequency of the CTLA4 +49AG SNP 
alleles between PSC patients and controls.  
 
Interestingly, in their recent report of CTLA4 associations in Grave’s disease, 
autoimmune hypothyroidism and type 1 diabetes, Ueda et al. (15) found that the 
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+49AG SNP was not implicated as the primary susceptibility determinant in either 
disease. Instead, the CT60 was the most strongly associated SNP and the genetic 
associations reported were weaker than expected from previous studies (OR=1.51 for 
the CT60 SNP in Grave’s disease and 1.14 for diabetes) (15). No association of the 
CT60 SNP to PSC was observed in the present study,   
 
This apparent variation in findings of studies of the genetic associations with CTLA4 
polymorphisms in autoimmune diseases can be explained by factors which threaten to 
undermine the validity of all genetic association studies (21): small sample sizes, 
selection bias, over use of multiple testing and random errors. In addition, true variation 
in the underlying association (i.e. allelic heterogeneity) may contribute to the 
inconsistency of reports. Our study had sufficient power to detect effects in PSC similar 
to those observed for the CTLA4 +49AG SNP in PBC (OR 1.9) and type I AIH (OR 
2.1). The lack of an association to the +49AG SNP in the present study indicates that 
there is no effect of this gene region on disease susceptibility in PSC. Alternatively, the 
study is not adequately powered to detect an association if existing. In the latter case, 
any genetic association must be weak (OR<1.8) and less pronounced than for PBC or 
type I AIH. The distributions of genotypes (Table II) and alleles (Table I) showed very 
little difference between patients and controls for both the CTLA4 +49AG and CT60 
SNPs. The most pronounced difference among these was found for the CT60*GG 
genotype which was 6% higher in patients than in controls, whereas the +49AG 
distribution varied by a maximum of 2% for any comparison. 
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All three genes tested in our study (CTLA4, CD28, and ICOS) are good candidate 
susceptibility genes for PSC. However, recent studies in other autoimmune diseases 
have failed to implicated either CD28 or ICOS as major or minor susceptibility genes 
(20;22). In accordance with these observations, we found no association of PSC with 
the CD28 or ICOS gene polymorphisms tested.  
 
Our study is important since it represents the first full publication addressing the issue 
of a possible contribution of CTLA4 to genetic susceptibility in PSC. To verify the 
possibility that CTLA4 may make a small contribution in this regard (i.e. OR ~ 1.1) as 
much as 7000 patients and controls will be required (allele frequency among controls 
0.5, power 80%, significance level 0.05). This is a sample size much larger than the 
currently available number of PSC patients worldwide. One can question the value of 
identifying very small genetic effects in disease. Small effects may be of less interest if 
the purpose is to identify genes to be used in population screening or for development 
of prognostic markers used in patient management and treatment. However, even small 
genetic contributions may be of major importance and give valuable information for 
understanding of the disease pathogenesis (7). Analysis of clinical subgroups of 
patients is also a valuable pursuit. This strategy has given new insight into the genetics 
of Crohn’s disease (23). Genetic heterogeneity has for long been known in PSC and 
recently it has been found that there may be significant phenotype/genotype 
correlations with both MHC and non-MHC genes (24;25). However, no particular 
subgroup associations were seen in the present study. 
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In conclusion, our study does not lend support to the possibility of a genetic association 
between PSC and the CTLA4, CD28 or ICOS genes. This observation is in keeping with 
the preliminary observations reported by Agarwal et al. (14). However, one can not 
exclude on statistical grounds, the possibility that either of these studies have failed to 
detect weak associations due to the relatively small numbers included. 
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Alleles
 PSC patients 
frequencies 
n=141
 Control 
frequencies 
n=263 OR p 1 p c2
Global p 
value3
CD28-A 0.5
231 0.05 0.04 1.3
235 0.85 0.84 1.1
237 0.05 0.05 1.0
other4 0.05 0.07 0.7
CD28-B 0.8
198 0.38 0.39 1.0
200 0.16 0.17 0.9
202 0.15 0.13 1.1
204 0.30 0.30 1.0
other4 0.02 0.01 1.9
SARA43 0.02*
218 0.13 0.13 1.0
220 0.11 0.05 2.3 0.003 0.08
222 0.48 0.54 0.8
224 0.11 0.08 1.4
226 0.12 0.13 0.9
other4 0.06 0.06 0.9
CT60 0.3
A 0.41 0.45 0.8
G 0.59 0.55 1.2
+49AG 0.9
A 0.61 0.60 1.0
G 0.39 0.40 1.0
SARA1 0.1
260 0.04 0.06 0.6
264 0.39 0.33 1.3
268 0.21 0.28 0.7
272 0.33 0.31 1.1
other4 0.04 0.03 1.4
SARA31 0.7
211 0.50 0.52 0.9
217 0.50 0.48 1.1
SARA47 0.5
149 0.31 0.33 0.9
151 0.37 0.34 1.1
153 0.28 0.26 1.1
other4 0.04 0.06 0.7
1Only statistically significant p  values are listed (p<0.05)
2Correction factor 30
4Alleles with frequencies less than 0.05 are grouped together
*5 degrees of freedom
Table I. Allele frequencies and global p values for selected genetic 
markers on chromosome 2q33 in Norwegian PSC patients and controls
3Global differences in distribution of alleles between PSC patients and controls at each 
locus tested by χ2 test or Ficher's exact test when appropriate. p  not corrected
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 PSC patients 
frequencies 
n=141
 Control 
frequencies 
n=263 OR p 1
Genotypes
CT60
AA 0.16 0.19 0.8
AG 0.49 0.52 0.9
GG 0.35 0.29 1.3
+49AG
AA 0.36 0.36 1.0
AG 0.49 0.47 1.1
GG 0.15 0.17 0.9
Carrier state
CT60
A 0.65 0.71 0.8
G 0.84 0.81 1.2
+49AG
A 0.85 0.83 1.1
G 0.64 0.64 1.0
Haplotype 
CT60-+49AG
A-A 0.41 0.44 0.9
A-G 0.00 0.01 0.2
G-A 0.20 0.16 1.4
G-G 0.39 0.40 1.0
1Only statistically significant p  values are listed (p <0.05)
Table II. Genotype, carrier and haplotype frequencies 
for the CTLA4 CT60  and +49AG  SNP
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Suggested location of Figure 1 after Statistical analyses and before Results. 
 
Figure legend 1 
Location of microsatellite markers (CD28A, CD28B, SARA43, SARA1, SARA31, 
SARA47) and single nucleotide polymorphisms (SNPs: CT60 and CTLA4 +49AG) in 
relation to the cluster of differentiation molecule 28 (CD28)-, the cytotoxic T 
lymphocyte antigen 4 (CTLA4)-, and the inducible co-stimulatory molecule (ICOS) 
genes on chromosome 2q33. Genes marked as grey boxes and distances are indicated in 
kilo-bases (kb). 
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Figure 1 
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